PharmCAT.NET

Биостатистика, фармакокинетика и клинические исследования.

  • Домашняя страница
    • О сайте
  • Материалы
    • Быстрые команды R Project
    • Ссылки
  • Инструменты
    • Рандомизационный список
  • Блог
    • Статистика
    • Phoenix WinNonlin
    • IT
    • Путевые заметки
  • Контакты
    • Контактные данные
    • Консультации
    • Конфиденциальность
  • Профиль
    • Войти
    • Зарегистрироваться

Adaptive Designs for Clinical Trials of Drugs and Biologics Guidance for Industry – FDA

Опубликовано 3 октября, 201817 декабря, 2018 frozencat

Обновление руководства FDA:

Adaptive Designs for Clinical Trials of Drugs and Biologics Guidance for Industry

Руководство замещает Adaptive Design Clinical Trials for Drugs and Biologics – 2010.

Рубрики: Блог

Навигация по записям

Предыдущая запись: Определение объема выборки для исследований биоэквивалентности с использованием компьютерного моделирования
Следующая запись: Работа с данными в IBM SPSS: присвоение меток переменным из другого источника

Свежие записи

  • Long WS Wide: или про то, как выполнить анализ разницы изменений между группами
  • Частые вопросы: Регистрация и экспертиза по правилам ЕАЭС
  • Главные ошибки при формировании базы данных в MS Excel
  • Тест ClinicalTrialUtilities и ReplicateBE на Raspberry Pi 4
  • Julia:ReplicateBE – release 0.2.0

Галерея

20180815 151848
20170802 181024
20180202 170847
20170803 172540
IMG-20170806-WA0029
20170730 151435
  • Human medicines European public assessment report (EPAR): Rivastigmine Actavis, rivastigmine, Date of authorisation: 16/06/2011, Revision: 21, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-06-13
  • UPDATED: Jarman’s Midwest Cleaning Systems, Inc. Issues Voluntary Nationwide Recall of Alcohol Antiseptic 80% Topical Solution Hand Sanitizer & Isopropyl Alcohol Antiseptic 75% Topical Solution Hand Sanitizer Due to Presence of Methanol
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-06-13 By FDA
  • Human medicines European public assessment report (EPAR): Ahzantive, aflibercept, Date of authorisation: 13/01/2025, Revision: 2, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-06-13
  • Human medicines European public assessment report (EPAR): Baiama, aflibercept, Date of authorisation: 13/01/2025, Revision: 1, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-06-13
  • Human medicines European public assessment report (EPAR): Humira, adalimumab, Date of authorisation: 08/09/2003, Revision: 94, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-06-13
  • MRESVIA
    Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2025-06-13 By FDA
  • Human medicines European public assessment report (EPAR): Viread, tenofovir disoproxil, Date of authorisation: 04/02/2002, Revision: 60, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-06-13
  • FDA Rare Disease Innovation Hub
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-06-13 By FDA
  • ANDAs: Pre-Submission Facility Correspondence Related to Prioritized Generic Drug Submissions
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-06-13 By FDA
  • Human medicines European public assessment report (EPAR): Invokana, canagliflozin, Date of authorisation: 15/11/2013, Revision: 26, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-06-13
  • Generic Drug Facilities, Sites and Organization Lists
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-06-13 By FDA
  • FDA approves neoadjuvant and adjuvant pembrolizumab for resectable locally advanced head and neck squamous cell carcinoma
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-06-13 By FDA
  • 2025 Biological License Application Approvals
    Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2025-06-12 By FDA
  • ANDA Assessment Program | GDUFA III Performance Goals and Program Enhancements
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-06-12 By FDA
  • Newly Added Guidance Documents
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-06-12 By FDA
Предыдущие записи
Тема: Scaffold от Danny Cooper.